Stockscreener 앱 받기
1.71
22.14%
0.31
시장 영업 전:
1.73
0.02
+1.17%
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
What analysts say about Neumora Therapeutics Inc. stockExceptional trading results - Jammu Links News
How Neumora Therapeutics Inc. stock reacts to Fed policy changesProven High Yield Signals - Newser
Neumora Therapeutics (NASDAQ:NMRA) Given New $5.00 Price Target at Mizuho - MarketBeat
Mizuho raises Neumora Therapeutics stock price target on new drug candidate - Investing.com Canada
Why Neumora Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
How Neumora Therapeutics Inc. stock performs during market volatilityCarefully Curated High Return Stocks - Newser
What makes Neumora Therapeutics Inc. stock price move sharplyReturn Optimized Trade Insights - Newser
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
FibroBiologics (NASDAQ:FBLG) vs. Neumora Therapeutics (NASDAQ:NMRA) Head to Head Contrast - Defense World
Neumora Therapeutics (NMRA) Soars 33.02% on Drug Trial Advancement - AInvest
H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Neumora begins phase 1 trial of schizophrenia drug NMRA-861 By Investing.com - Investing.com South Africa
Neumora Therapeutics’ Promising M4 PAM Program Drives Buy Rating with $18 Price Target - TipRanks
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 - The Manila Times
Neumora begins phase 1 trial of schizophrenia drug NMRA-861 - Investing.com
Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks - simplywall.st
Lunate Capital Ltd Acquires Shares of 2,124,143 Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus Target Price from Analysts - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by California State Teachers Retirement System - Defense World
72,622 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Shareholders Filed a Lawsuit Against Neumora Therapeutics for Misleading Drug Trial Claims - TradingView
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Hold” by Analysts - Defense World
Ameriprise Financial Inc. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics Holds Annual Stockholders Meeting - TipRanks
BNP Paribas Financial Markets Invests $221,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Deutsche Bank AG Has $775,000 Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Kuehn Law Encourages Investors of Grocery Outlet Holding Corp. to Contact Law Firm - GlobeNewswire Inc.
26,500 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Bought by Janus Henderson Group PLC - Defense World
Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development - Investing.com India
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Softbank Group CORP. Sells 1,005,726 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics Q1 2025: Unraveling Contradictions in KOASTAL Trials and Patient Selection Strategies - AInvest
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by Northern Trust Corp - Defense World
Orbimed Advisors LLC Has $8.53 Million Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
HC Wainwright Has Pessimistic Outlook of NMRA Q2 Earnings - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk - Investing.com Australia
The Manufacturers Life Insurance Company Has $478,000 Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MD - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com India
Neumora Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Neumora Therapeutics Inc On May 14, Receives Nasdaq Non-Compliance Notice - marketscreener.com
What is HC Wainwright’s Forecast for NMRA Q2 Earnings? - Defense World
William Blair Analysts Increase Earnings Estimates for NMRA - Defense World
Neumora Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
0.64%
0.37%
자본화:
|
볼륨(24시간):